Search Results - "Mockeliūnas, Laurynas"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19 by van Wijk, Rob C., Mockeliunas, Laurynas, van den Hoogen, Gerben, Upton, Caryn M., Diacon, Andreas H., Simonsson, Ulrika S. H.

    Published in Scientific reports (28-09-2023)
    “…Large clinical trials often generate complex and large datasets which need to be presented frequently throughout the trial for interim analysis or to inform a…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development by Mockeliunas, Laurynas, Faraj, Alan, van Wijk, Rob C, Upton, Caryn M, van den Hoogen, Gerben, Diacon, Andreas H, Simonsson, Ulrika S H

    Published in Frontiers in pharmacology (2023)
    “…A critical step in tuberculosis (TB) drug development is the Phase 2a early bactericidal activity (EBA) study which informs if a new drug or treatment has…”
    Get full text
    Journal Article
  5. 5

    Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment by Keutzer, Lina, Mockeliunas, Laurynas, Sturkenboom, Marieke G. G, Bolhuis, Mathieu S, Akkerman, Onno W, Simonsson, Ulrika S. H

    Published in Pharmaceuticals (Basel, Switzerland) (01-11-2023)
    “…Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75…”
    Get full text
    Journal Article
  6. 6

    Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling by van Wijk, Rob C, Mockeliunas, Laurynas, Upton, Caryn M, Peter, Jonathan, Diacon, Andreas H, Simonsson, Ulrika S H

    “…Respiratory tract infections (RTIs) are a burden to global health, but their characterization is complicated by the influence of seasonality on incidence and…”
    Get full text
    Journal Article
  7. 7

    Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis by Mockeliunas, Laurynas, Keutzer, Lina, Sturkenboom, Marieke G G, Bolhuis, Mathieu S, Hulskotte, Lotte M G, Akkerman, Onno W, Simonsson, Ulrika S H

    Published in Pharmaceutics (30-03-2022)
    “…Linezolid is an efficacious medication for the treatment of drug-resistant tuberculosis but has been associated with serious safety issues that can result in…”
    Get full text
    Journal Article
  8. 8

    Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic by Mockeliunas, Laurynas, van Wijk, Rob C, Upton, Caryn M, Peter, Jonathan, Diacon, Andreas H, Simonsson, Ulrika S H

    Published in Vaccines (Basel) (01-03-2024)
    “…(1) Background: Some individuals are more susceptible to developing respiratory tract infections (RTIs) or coronavirus disease (COVID-19) than others. The aim…”
    Get full text
    Journal Article
  9. 9

    OA-83 Early bactericidal activity of meropenem, ertapenem, amoxicillin/clavulanate and optimized rifampicin in pulmonary tuberculosis by Upton, Caryn, Jager, Veronique De, Simonsson, Ulrika, Mockeliunas, Laurynas, Mabuka, Thabo, Lelievre, Joel, Sharma, Raman, Chen, Chao, Barros, David, Diacon, Andreas

    Published in BMJ global health (17-12-2023)
    “…BackgroundRepurposing established antibiotics for TB has been successful, notably for fluoroquinolones, linezolid, and clofazimine. Meropenem co-administered…”
    Get full text
    Journal Article